Stephen V Liu: Data from ARROS-1 study of NVL-520 in ROS1 NSCLC

Stephen V Liu shared a post on X:

”Benjamin Besse presents data from ARROS-1 study of NVL-520 (zidesamtinib) in ROS1 non-small cell lung cancer (NSCLC). Recommended Phase 2 Dose (RP2D) established at 100mg daily. Rationally designed drug with high central nervous system (CNS) efficacy and avoiding tropomyosin receptor kinase (TRK) will help reduce toxicity.

Impressive activity of NVL-520 (zidesamtinib) in ROS1 non-small cell lung cancer (NSCLC). Overall response rate (ORR) 44%; in repotrectinib naive setting, response rate (RR) 51%. With ROS1 G2032R, response rate (RR) 72% if repotrectinib naive. Durable responses (median not reached in repotrectinib naive). Strong intracranial efficacy.

Importantly, very favorable safety profile, largely from sparing tropomyosin receptor kinase (TRK) signaling. Main toxicities include edema, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevation, weight gain – but none leading to discontinuation and dose reduction rate from treatment-related adverse events (TRAE) only 8%.”

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.

Benjamin Besse is the Head of Clinical Research at Gustave Roussy and a Full Professor of Medical Oncology at University of Paris-Saclay. He serves as the Chair of the Scientific Council at EORTC and is the Coordinator of RYTHMIC, the French thymic malignancies network. His research is centered on personalized therapeutic strategies, focusing on molecular abnormalities, circulating biomarkers, and early drug development for thymic malignancies and thoracic tumors.